The B/B genotype of the AGT promoter was associated with higher odds of microangiopathy-related cerebral damage compared to the remaining cohort (OR 8.0; 95% CI 2.1-31.1; P=0.003).
Cross-Sectional (n=410)
Is the angiotensinogen gene promoter B haplotype associated with microangiopathy-related cerebral damage in community-dwelling older adults?
The B haplotype of the angiotensinogen gene promoter may represent a genetic susceptibility factor for microangiopathy-related cerebral damage.
Odds Ratio: 8 (95% CI 2.1–31.1)
Absolute Event Rate: 63.6% vs 19%
p-value: p=0.003
BACKGROUND AND PURPOSE: Microangiopathy-related cerebral damage (MARCD) is a common finding in the elderly. It may lead to cognitive impairment and gait disturbances. Arterial hypertension and age are the most important risk factors. We assessed the association between MARCD and sequence alterations in the promoter region of the angiotensinogen (AGT) gene. METHODS: We studied 410 randomly selected community-dwelling individuals aged 50 to 75 years. MARCD was defined as early confluent or confluent white matter hyperintensities or lacunes on a 1.5-T MRI. The AGT promoter was analyzed by temporal temperature gradient gel electrophoresis and automated sequencing. RESULTS: We detected 4 polymorphic sites, at positions -6, -20, -153, and -218. They created 5 haplotypes, which we coded as A (-6:g, -20:a, -153:g, -218g), B (-6:a, -20:c, -153:g, -218:g), C (-6:a, -20:c, -153:a, -218:g), D (-6:a, -20:a, -153:g, -218:g), and E (-6:a, -20:a, -153:g, -218:a). MARCD was seen in 7 subjects (63.6%) carrying 2 copies of the B haplotype (B/B), in 12 subjects (38.7%) carrying 1 copy of the B haplotype in the absence of the A haplotype (B+/A-), but in only 70 subjects (19.0%) in the remaining cohort (P:<0.001). The odds ratios for the B/B and the B+/A- genotypes were 8.0 (95% CI, 2.1 to 31.1; P:=0.003) and 1.8 (95% CI, 0.8 to 4.2; P:=0.14) after adjustment for possible confounders. CONCLUSIONS: The B haplotype of the AGT promoter in the absence of the wild-type A haplotype might represent a genetic susceptibility factor for MARCD.
Schmidt et al. (Thu,) conducted a cross-sectional in Microangiopathy-related cerebral damage (MARCD) (n=410). B/B genotype of the AGT promoter vs. Remaining cohort was evaluated on Microangiopathy-related cerebral damage (MARCD) (OR 8.0, 95% CI 2.1 to 31.1, p=0.003). The B/B genotype of the AGT promoter was associated with higher odds of microangiopathy-related cerebral damage compared to the remaining cohort (OR 8.0; 95% CI 2.1-31.1; P=0.003).